Promising Celiac Disease Treatment

How TEV-408 Targets Celiac Disease

TEV-408 is a monoclonal antibody that blocks interleukin-15, a protein involved in the immune response that damages the small intestine in celiac disease. Northern News explains that the drug works by reducing intestinal inflammation triggered by gluten exposure. Celiac disease affects about 1 in 100 people globally and currently has no cure — patients must avoid gluten entirely.

1 source

What the Phase 2a Study Showed

In the trial, patients who received a single TEV-408 injection showed statistically significant prevention of intestinal damage when exposed to gluten. The Sudbury Star reported that the drug also reduced intestinal inflammation markers compared to the control group. No serious safety issues emerged during the study period.

This early-stage result is particularly encouraging because it required only one dose to achieve protection. Typical celiac treatments require ongoing dietary restriction. The positive data moves the drug closer to larger, later-stage testing needed for regulatory approval.

1 source

Teva's Broader Pipeline Strategy

Teva describes TEV-408 as part of its "pipeline-in-a-product" approach, meaning the company is developing multiple uses for anti-IL-15 technology beyond celiac disease. Sault Star reports that blocking IL-15 may help treat other immune-related conditions as well. This strategy allows Teva to maximize the commercial potential of a single drug platform across different diseases.

The company plans to share additional study details at a future medical conference. An investor call will discuss next steps, including timing for Phase 2b or Phase 3 trials. If development continues successfully, TEV-408 could reach patients within several years.

1 source